PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...
In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...
Event-free survival improved with EV/pembro: median not reached vs 48.5 months, and 24‑month EFS 79.4% vs 66.2% with cisplatin/gemcitabine. Overall survival separated early (24‑month 86.9% vs 81.3%), ...
Keytruda and Padcev combination shows improved event-free and overall survival in muscle invasive bladder cancer patients ineligible for cisplatin. The KEYNOTE-905/EV-303 trial demonstrated ...
News provided by Astellas Pharma Inc. Oct 21, 2025, 7:30 PM ET Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of ...
A combination of Pfizer and Astellas’ Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) has offered significant improvements to patient outcomes compared with standard of care (SoC) ...
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results